# RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

> **NCT00936858** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 50 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT00936858
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2020-02-27
- **Final completion:** 2020-02-27
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-10-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00936858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00936858, "RAD001 for Patients With Radioiodine Refractory Thyroid Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00936858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*